Regentis Biomaterials shares surged more than 200% to $4.11 after the company said it plans to begin European surgeon training in Q3, advancing the commercial rollout of GelrinC in Europe. The update signals progress toward launch execution and appears to be driving a sharp speculative re-rating in the stock.
Regentis Biomaterials shares surged more than 200% to $4.11 after the company said it plans to begin European surgeon training in Q3, advancing the commercial rollout of GelrinC in Europe. The update signals progress toward launch execution and appears to be driving a sharp speculative re-rating in the stock.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.72
